DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have been assigned an average recommendation of “Moderate Buy” from the five brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $14.75.

A number of brokerages have commented on DBVT. HC Wainwright increased their price target on shares of DBV Technologies from $7.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, May 5th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a report on Tuesday, May 27th. Wall Street Zen cut shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Friday, July 18th. The Goldman Sachs Group raised DBV Technologies to a “sell” rating and set a $7.25 price objective for the company in a research report on Thursday, May 29th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 price target on shares of DBV Technologies in a research report on Thursday, June 26th.

Institutional Trading of DBV Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the business. Boxer Capital Management LLC acquired a new stake in DBV Technologies in the fourth quarter worth about $154,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of DBV Technologies during the second quarter worth about $9,659,000. MPM Bioimpact LLC acquired a new stake in shares of DBV Technologies during the second quarter worth about $9,649,000. Octagon Capital Advisors LP acquired a new stake in shares of DBV Technologies during the second quarter worth about $9,315,000. Finally, Vivo Capital LLC acquired a new stake in shares of DBV Technologies during the second quarter worth about $9,659,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Price Performance

Shares of DBVT stock opened at $9.99 on Friday. The company has a market cap of $273.63 million, a P/E ratio of -2.09 and a beta of -0.58. The firm has a 50-day moving average of $9.73 and a 200-day moving average of $7.77. DBV Technologies has a one year low of $2.20 and a one year high of $12.78.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Tuesday, July 29th. The company reported ($1.55) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.34). The business had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $0.64 million. DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%. As a group, research analysts expect that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.